Aptevo Therapeutics

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / ACCESSWIRE / May 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced positive results from the Company's Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). APVO436 was generally well tolerated and demonstrated a favorable side effect profile, including the absence of severe or prolonged neutropenia, an often serious condition associated with CD123-targeting therapies.

Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the quarter ended March 31, 2021. "We are pleased to report progress in the clinical trial of our ADAPTIR platform candidate APVO436, with the dose limiting toxicity (DLT) evaluation in cohorts 1 through 9 now completed and 44 patients enrolled to date in cohorts 1-10.

Aptevo Therapeutics Reports First Quarter 2021 Financial Results

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021. The posters will provide preclinical updates on APVO603 and Aptevo's newest pipeline candidate, APVO442.

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Agreement SEATTLE, WA / ACCESSWIRE / March 31, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its financial results for the year ended December 31, 2020, provided a clinical update, announced the sale of RUXIENCE royalty payments and responded to an indication of interest from Tang Capital Partners, LP ("TCP"). "We are very pleased with our performance in 2020 and believe we are well positioned for 2021 and beyond.

Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update

An Assessment On Aptevo Therapeutics

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial. The Company noted that patient dosing in cohorts 1 through 8 has been completed and enrollment in cohort 9 has commenced.

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.

Aptevo: Positive Early Stage Data Makes This Highly Interesting

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology...

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today appeared first on InvestorPlace.

Aptevo Therapeutics News: Why APVO Stock Is Falling 15% Today

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.

APVO Stock Price Increases By 78.25%: Why It Happened

Blink Charging

Energy Focus

Second Sight Medical Products

SG Blocks

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three indices.

Top Stocks To Short As Nasdaq Sets New Intraday Record

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy

Is  (APVO) Outperforming Other Medical Stocks This Year?

Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq...

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.

Why Aptevo Therapeutics Is Trading Higher Today

What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock

SEATTLE, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML and myelodysplastic syndrome (MDS).

Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia

Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.

Aptevo Therapeutics: Profitability Might Be 12 Months Away

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay

Aptevo Therapeutics Provides Corporate and Pipeline Update

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific  Antibody Targeting 4-1BB and OX40

Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

IXINITY revenue increased for the quarter, which is what I wanted to see.

Aptevo Therapeutics: IXINITY Revenue Still The Focus

Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.

News for Aptevo Therapeutics Stock (APVO)